Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Development of Parkinson's disease in patients with Narcolepsy.

Christine CW, Marks WJ Jr, Ostrem JL.

J Neural Transm (Vienna). 2012 Jun;119(6):697-9. doi: 10.1007/s00702-011-0761-z. Epub 2012 Jan 10.

PMID:
22231845
2.

[Narcolepsy: a new perspective on diagnosis and treatment].

Fronczek R, van der Zande WL, van Dijk JG, Overeem S, Lammers GJ.

Ned Tijdschr Geneeskd. 2007 Apr 14;151(15):856-61. Review. Dutch. Erratum in: Ned Tijdschr Geneeskd. 2007 Jun 2;151(22):1260.

PMID:
17472116
3.

Emerging treatments for narcolepsy and its related disorders.

Nishino S, Okuro M.

Expert Opin Emerg Drugs. 2010 Mar;15(1):139-58. doi: 10.1517/14728210903559852. Review.

PMID:
20166851
4.
5.

Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin.

Morgenthaler TI, Kapur VK, Brown T, Swick TJ, Alessi C, Aurora RN, Boehlecke B, Chesson AL Jr, Friedman L, Maganti R, Owens J, Pancer J, Zak R; Standards of Practice Committee of the American Academy of Sleep Medicine.

Sleep. 2007 Dec;30(12):1705-11. Review. Erratum in: Sleep. 2008 Feb 1;31(2):table of contents.

6.

Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Smith Y, Wichmann T, Factor SA, DeLong MR.

Neuropsychopharmacology. 2012 Jan;37(1):213-46. doi: 10.1038/npp.2011.212. Epub 2011 Sep 28. Review.

7.

Moderate Parkinson's disease. Strategies for maximizing treatment.

Silverstein PM.

Postgrad Med. 1996 Jan;99(1):52-4, 61-3, 67-8, passim. Review.

PMID:
8539210
8.

Can we achieve neuroprotection with currently available anti-parkinsonian interventions?

Olanow CW.

Neurology. 2009 Feb 17;72(7 Suppl):S59-64. doi: 10.1212/WNL.0b013e318199068b. Review.

PMID:
19221316
9.

Perspectives in narcolepsy research and therapy.

Mignot E.

Curr Opin Pulm Med. 1996 Nov;2(6):482-7. Review.

PMID:
9363189
10.
11.
12.

Parkinson's disease: recent development in therapies for advanced disease with a focus on deep brain stimulation (DBS) and duodenal levodopa infusion.

Sydow O.

FEBS J. 2008 Apr;275(7):1370-6. doi: 10.1111/j.1742-4658.2008.06295.x. Epub 2008 Feb 12. Review.

13.

Treatment challenges in early stage Parkinson's disease.

Tetrud J.

Neurol Clin. 2004 Oct;22(3 Suppl):S19-33. Review. No abstract available.

PMID:
15501364
14.

[Diagnosis and therapy of idiopathic Parkinson's disease].

Reichmann H.

MMW Fortschr Med. 2006 May 15;Spec no. 2:54, 56-8, 60-1. Review. German.

PMID:
20104716
15.

Parkinson's Disease: From Pathogenesis to Pharmacogenomics.

Cacabelos R.

Int J Mol Sci. 2017 Mar 4;18(3). pii: E551. doi: 10.3390/ijms18030551. Review.

16.

Neuroprotection for Parkinson's disease.

Koller WC.

Ann Neurol. 1998 Sep;44(3 Suppl 1):S155-9. Review.

PMID:
9749588
17.

Dopamine agonists and neuroprotection in Parkinson's disease.

Olanow CW, Jenner P, Brooks D.

Ann Neurol. 1998 Sep;44(3 Suppl 1):S167-74. Review.

PMID:
9749590
18.

Adenosine A2A antagonists: potential preventive and palliative treatment for Parkinson's disease.

Morelli M.

Exp Neurol. 2003 Nov;184(1):20-3. Review. No abstract available.

PMID:
14637073
19.

Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.

Henchcliffe C, Schumacher HC, Burgut FT.

Expert Rev Neurother. 2005 Nov;5(6):811-21. Review.

PMID:
16274338
20.

Treatment of early Parkinson's disease. Part 2.

Simuni T, Lyons KE, Pahwa R, Hauser RA, Comella C, Elmer L, Weintraub D.

Eur Neurol. 2009;61(4):206-15. doi: 10.1159/000197104. Epub 2009 Jan 29. Review.

Supplemental Content

Support Center